EMPAGLIFLOZIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE, AND ITS EFFECT ON VENTRICULAR ARRHYTHMIAS
https://doi.org/10.35266/2304-9448-2023-2-59-62
Abstract
The study aims to assess empagliflozin affecting ventricular dysrhythmia and late potential of ventricles in patients with chronic heart failure with low etiology ejection fraction. The study included 35 male patients (61.7 ± 11.2 years old) who received standard therapy, followed by 10 mg empagliflozin in 6 months. The examination included echocardioscopy, 12-leads electrocardiography, signal-averaged electrocardiography, and daily electrocardiography monitoring. 10 mg empagliflozin added to the standard therapy provided for a statistically significant decrease in the number of single premature heart beats by 67.7 % (p = 0.001), in the episodes of unstable ventricular tachycardia by 74.5 % (p = 0.001), in the frequency of late ventricular potential by 31 % (Chisquare = 5.51; р = 0.019), and for a statistically insignificant trend to ejection fraction increase (p > 0.05).
About the Authors
V. A. Razin
Ulyanovsk State University, Ulyanovsk
Russian Federation
Russian Federation
Doctor of Sciences (Medicine), Docent, Professor
E-mail: razin1975@mai.ru
A. A. Tsareva
Ulyanovsk Regional Clinical Hospital, Cardiology Department No. 2, Ulyanovsk
Russian Federation
Russian Federation
Cardiologist
E-mail: nastasya_zareva@mail.ru
References
1. Хроническая сердечная недостаточность: клинич. рекомендации. 2020 // Российский кардиологический журнал. 2020. Т. 25, № 11. С. 4083. DOI 10.15829/1560-4071-2020-4083.
2. Ni L., Yuan C., Chen G. et al. SGLT2i: Beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1):98.
3. Zinman B., Wanner C., Lachin J. M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
4. Curtain J. P., Docherty K. F., Jhund P. S. et al. Effect of dapagliflozin onventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727–3738.
5. Fujiki S., Iijima K., Okabe M. et al. Placebo-controlled, double-blind study of empagliflozin (EMPA) and implantable cardioverter-defibrillator (EMPA ICD) in patients with type 2 diabetes (T2DM): rationale and design. Diabetes Ther. 2020;11(11):2739–2755.
6. Ilyas F., Jones L., Tee S. L. et al. Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: A crossover trial. ESC Heart Fail. 2021;8(5):4346–4352.
7. Byrne N. J., Matsumura N., Maayah Z. H. et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide- binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13(1):e006277.
8. Philippaert K., Kalyaanamoorthy S., Fatehi M. et al. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143(22):2188–2204.
9. Uthman L., Baartscheer A., Bleijlevens B. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61(3):722–726.
10. Light P. E. Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. Eur Heart J. 2021;42(36):3739–3740.
Review
For citations:
Razin V.A., Tsareva A.A. EMPAGLIFLOZIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE, AND ITS EFFECT ON VENTRICULAR ARRHYTHMIAS. Vestnik SurGU. Meditsina. 2023;16(2):59-62. (In Russ.) https://doi.org/10.35266/2304-9448-2023-2-59-62
Views:
108
Email this article 
